In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DermaFreeze365 recall

This article was originally published in The Rose Sheet

Executive Summary

Woodridge Labs is voluntarily recalling all DermaFreeze365 Instant Line Relaxing Formula and DermaFreeze365 Neck & Chest products after certain lots tested positive for bacteria, company announces March 23. The organism, Pseudomonas aeruginosa bacteria, may cause a number of systemic infections and is especially dangerous to people who are immunosuppressed, firm says. As Instant Line Relaxing Formula may be applied to the eye area, there is a risk of serious eye infections or blindness. The bacteria was discovered during routine testing and no illnesses have been reported to date, firm adds. Woodridge Labs notified retailers, distributors and the FDA on March 13 and is implementing a nationwide recall. The firm believes that the affected products contain a discoloration that is visible to the naked eye; consumers should discontinue use and destroy the product immediately, or return it to their place of purchase...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014622

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel